9.82
-0.07(-0.71%)
Currency In USD
| Previous Close | 9.89 |
| Open | 9.85 |
| Day High | 9.97 |
| Day Low | 9.78 |
| 52-Week High | 9.97 |
| 52-Week Low | 6.69 |
| Volume | 1.61M |
| Average Volume | 1.6M |
| Market Cap | 3.08B |
| PE | 982 |
| EPS | 0.01 |
| Moving Average 50 Days | 8.74 |
| Moving Average 200 Days | 8.16 |
| Change | -0.07 |
If you invested $1000 in Amneal Pharmaceuticals, Inc. (AMRX) since IPO date, it would be worth $654.23 as of September 11, 2025 at a share price of $9.82. Whereas If you bought $1000 worth of Amneal Pharmaceuticals, Inc. (AMRX) shares 5 years ago, it would be worth $2,675.75 as of September 11, 2025 at a share price of $9.82.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Amneal Receives U.S. FDA Approval for Risperidone Extended-Release Injectable Suspension
GlobeNewswire Inc.
Sep 04, 2025 8:01 PM GMT
Another addition to Amneal’s growing complex injectables portfolio reflects leadership in advanced development and manufacturing of complex pharmaceuticals BRIDGEWATER, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032
GlobeNewswire Inc.
Jul 21, 2025 11:39 AM GMT
BRIDGEWATER, N.J., July 21, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”) (Nasdaq: AMRX) announced that its subsidiary, Amneal Pharmaceuticals LLC (the “Issuer”), is seeking to borrow $1.800 billion aggregate principal amount of
Amneal to Report Second Quarter 2025 Results on August 5, 2025
GlobeNewswire Inc.
Jul 09, 2025 12:00 PM GMT
BRIDGEWATER, N.J., July 09, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Company will release its second quarter 2025 financial result